08:25 AM EST, 11/26/2024 (MT Newswires) -- Axsome Therapeutics ( AXSM ) said Tuesday that a late-stage trial of AXS-12, a narcolepsy drug candidate, had achieved its primary endpoint of statistically significant reduction in cataplexy attacks.

Treated patients who were switched to placebo had worsened attacks with an increase of 10.29 attacks per week, whereas those who continued AXS-12 treatment saw an increase of 1.32, Axsome said.

The drug also showed statistical significance in improving cognition and overall narcolepsy symptoms, the company said.

Shares of the company were up 2.8% in recent Tuesday premarket activity.

Price: 102.00, Change: +4.50, Percent Change: +4.6